Advertisement
Canada markets open in 7 hours 25 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7254
    -0.0010 (-0.14%)
     

  • CRUDE OIL

    84.49
    +1.76 (+2.13%)
     

  • Bitcoin CAD

    85,431.13
    +938.10 (+1.11%)
     

  • CMC Crypto 200

    1,288.23
    -24.40 (-1.83%)
     

  • GOLD FUTURES

    2,396.50
    -1.50 (-0.06%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,378.75
    -168.50 (-0.96%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    37,201.05
    -878.65 (-2.31%)
     

  • CAD/EUR

    0.6822
    +0.0001 (+0.01%)
     

Wall Street Fundamentals Releases New In-Depth Stock Reports on GERN, SNTA, SNTS and VPHM

ACCESSWIRE

The Biotech Industry has continued to outpace the broader markets in 2013. The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB - News) and the SPDR S&P Biotech ETF (NYSEARCA:XBI - News) have posted gains of approximately 53.0 and 49.0 percent, respectively, more than 2.5 times the S&P 500 Index’s gain of 19.0 percent. The red hot biotech market has already caused more biotech companies to go public in the first half of 2013, than all of 2012. Here is how some biotech companies reacted Thursday:

Geron Corporation (NASDAQ:GERN - News) shares traded in the range of $3.11 to $3.46 Thursday before settling to close at $3.35, an increase of 7.37 percent. The stock appears to have some support at the $3.09, $1.45 and $1.17 levels. Shares of Geron have gained approximately 135.0 percent in 2013.

More information on Geron and access to the free equity report can be found at:
www.WallStreetFundamentals.com/GERN

Synta Pharmaceuticals Corp. (NASDAQ:SNTA - News) shares traded in the range of $6.17 to $6.64 Thursday before settling to close at $6.53, an increase of 6.53 percent. The stock appears to be facing some resistance at the $6.86 and $7.19 levels with some support at $6.32. Shares of Synta Pharmaceuticals have fallen approximately 27.0 percent in 2013.

ADVERTISEMENT

More information on Synta Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/SNTA

Santarus, Inc. (NASDAQ:SNTS - News) shares traded in the range of $22.07 to $23.26 Thursday before settling to close at $22.98, an increase of 6.24 percent. The stock appears to be facing some resistance at the $23.79 and $24.25 levels with some support at $22.96. Shares of Santarus have gained approximately 110.0 percent in 2013.

More information on Santarus and access to the free equity report can be found at:
www.WallStreetFundamentals.com/SNTS

Viropharma Inc. (NASDAQ:VPHM - News) shares traded in the range of $38.91 to $39.81 Thursday before settling to close at $39.27, an increase of 0.20 percent. The stock appears to be facing some resistance at $40.78 with some support at the $39.12 and $36.59 levels. Shares of Viropharma have gained approximately 72.0 percent in 2013.

More information on Viropharma and access to the free equity report can be found at:
www.WallStreetFundamentals.com/VPHM

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at http://www.wallstreetfundamentals.com/ today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: http://www.wallstreetfundamentals.com/
Email: editor@wallstreetfundamentals.com